PHILADELPHIA, PA (PRWEB) NOVEMBER 20, 2015
The two newest residents of the University City Science Center’s Port business incubator are taking on oral pain management and developing next-generation oncology therapeutics.
FyMed is a pharmaceutical company focused on drug development through sophisticated biomarker discovery methodologies in precision medicine. Starting with products for oral pain management, FyMed is utilizing novel markers based on immunomodulation therapy using NSAIDs. FyMed’s lab is located at 3624 Market Street.
Click here for the full story.